Repligen receives research grants
Repligen Corp. of Waltham said today that it has received $1.125 million in research grants to support the development of new treatments for Friedreich's ataxia.
Friedreich's ataxia is an inherited neurodegenerative disease in which a single gene defect results in inadequate production of the protein frataxin, leading to progressive damage to the nervous system and loss of muscle function, the company noted.
The research grants are made up of $1 million from the Muscular Dystrophy Association and $125,000 from the Friedreich's Ataxia Research Foundation and the National Ataxia Foundation, the company said.
In a press release, Repligen said, "The grants will further the development, characterization, and selection of a drug candidate for human clinical trials as well as support the development of tools ('biomarkers') to monitor the desired biological impact of the drugs in clinical trials."
(By Chris Reidy, Globe staff)
